secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acumen Pharmaceuticals, Inc. (ABOS)
CIK:        0001576885
Form:       8-K
Filed at:   2021-11-10T23:59:59+00:00
Accession:  0001193125-21-325299
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acumen posts presentation on ACU193 Phase 1 trial design for early Alzheimer's disease
--------------------------------------------------------------------------------

- ACU193 is a monoclonal antibody that selectively targets toxic amyloid-beta oligomers for early Alzheimer's disease.
- The Phase 1 INTERCEPT-AD trial design is detailed in the presentation posted on November 10, 2021.
- The presentation is available on Acumen's website and was furnished to the SEC as Exhibit 99.1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576885/000119312521325299/0001193125-21-325299-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576885/000119312521325299/d234985d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-325299

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer